Diop Y, Toni TA, Bonard D, Ba-Gomis FO, Sia E, Nguyen VK, Chenal H; International Conference on AIDS.
Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. TuPeB4469.
CIRBA/FMRPS, ABIDJAN, Cote d'Ivoire
BACKGROUND: To date, there have been no prospective clinical trials of HAART in West Africa. This study was conducted to examine whether standard triple combination therapy with Combivir and Indinavir was effective in this setting. The study was conducted over 2 years. METHODS: Subjects were recruited from patients attending CIRBA, a private treatment and research centre in Abidjan,Cote d'Ivoire. Inclusion criteria: CD4>100, VL>10 000, ARV naive, no intercurrent OIs or malignancies. 20 patients were enrolled from October 1999 to January 2000. RESULTS: Follow-up after 22 months: 14 patients have reached 22 months 1 patient 20 months 1 patient 18 months 1 patient 16 months 1 patient 9 months 1 patient 4 months 1 patient 2 months 4 patients are lost to follow-up Proportion reaching < 200 copies at this term = 11(55%) 4 patients had their VL decreased significantly 3 patients reached <200 copies,then incresed because they stopped the ARVs 2 had increased because of non adherence to ARV treatment Total days of observation 566+/-188.6 days Mean time to indetectable 150+/-67.6 days Mean CD4 at baseline 314+/-131 cell/mm3 Mean CD4 at end 575+/-275 cell/mm3 Mean VL at baseline 4.8+/-0.7 log Mean VL at end 3.2+/-1.2 log Difference in CD4 and VL between baseline and end was statistically significant (p< 0.05 and p<0.001) CONCLUSION: Ttiple therapy is effective in this urban, West African setting. Because of response to treatment is link to adherance ( adherence and side effects ), it is indispensable to have strict follow-up.
Publication Types:
Keywords:
- Africa
- Antiretroviral Therapy, Highly Active
- Clinical Trials as Topic
- Combivir
- Cote d'Ivoire
- Humans
- Indinavir
- Lamivudine
- Longitudinal Studies
- Prospective Studies
- Zidovudine
Other ID:
UI: 102255847
From Meeting Abstracts